Pharmaceutical company Bayer has received approval from the European Commission for a pre-filled syringe to administer aflibercept (marketed as Eylea) for the treatment of retinal conditions.
Bayer explained that the pre-filled syringe provides practitioners with a new, streamlined method of administration, which requires fewer steps to prepare for intravitreal injection than the vial.
Dr Jackie Napier, medical director of ophthalmology at Bayer, said: ‘We are delighted that aflibercept is now available for use in a pre-filled syringe, in addition to the standard glass vial, enabling physicians to choose the option that works best for them, their patients and the efficiency of their clinic.’
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here
